Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net sales	$ 11,888	$ 9,913	$ 10,735
Cost of products sold	3,711	3,465	3,116
Gross profit	8,177	6,448	7,620
Operating expenses:
Selling, general and administrative expenses	4,359	3,787	3,941
Research and development expenses	1,204	1,143	1,174
Royalty expense	49	45	65
Amortization expense	741	789	699
Goodwill impairment charges	0	73	0
Intangible asset impairment charges	370	460	105
Contingent consideration net expense (benefit)	(136)	(100)	(35)
Restructuring net charges (credits)	40	52	38
Litigation-related net charges (credits)	430	278	115
Gain (Loss) on Disposition of Assets	(78)	0	0
Operating expenses	6,978	6,528	6,102
Operating income (loss)	1,199	(80)	1,518
Other income (expense):
Interest expense	(341)	(361)	(473)
Other, net	218	362	(358)
Income (loss) before income taxes	1,076	(79)	687
Income tax (benefit) expense	36	2	(4,013)
Net income (loss)	1,041	(82)	4,700
Preferred stock dividends	55	33	0
Net income (loss) available to common stockholders	$ 985	$ (115)	$ 4,700
Net income (loss) per common share — basic	$ 0.69	$ (0.08)	$ 3.38
Net income (loss) per common share — assuming dilution	$ 0.69	$ (0.08)	$ 3.33
Weighted-average shares outstanding
Basic	1,422,300	1,416,700	1,391,500
Assuming dilution	1,433,800	1,416,700	1,410,600